Cargando…
Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance
Lung cancer is the leading cause of cancer deaths in the world. At present, immunotherapy has made a great breakthrough in lung cancer treatment. A variety of immune checkpoint inhibitors have been applied into clinical practice, including antibodies targeting the programmed cell death-1, programmed...
Autores principales: | Kong, Fanming, Wang, Ziwei, Liao, Dongying, Zuo, Jinhui, Xie, Hongxia, Li, Xiaojiang, Jia, Yingjie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438235/ https://www.ncbi.nlm.nih.gov/pubmed/34532293 http://dx.doi.org/10.3389/fonc.2021.739191 |
Ejemplares similares
-
Research Progress of Antibody–Drug Conjugate Therapy for Advanced Gastric Cancer
por: Wang, Na, et al.
Publicado: (2022) -
Research Progress on RET Fusion in Non-Small-Cell Lung Cancer
por: Zhao, Lu, et al.
Publicado: (2022) -
The Clinical Observation of Acupuncture Combined With Antiemetic Drugs in the Prevention and Treatment of CINV in Breast Cancer Patients
por: Kong, Fanming, et al.
Publicado: (2022) -
Advances in Immunotherapy of Malignant Pleural Mesothelioma
por: Liao, Dongying, et al.
Publicado: (2021) -
Advances in Antibody-Drug Conjugates in the Treatment of HER2-Positive Breast Cancer
por: Yu, Yongchao, et al.
Publicado: (2022)